Get the Stockscreener App
1.3365
1.16%
0.0165
Oragenics Inc stock is traded at $1.3365, with a volume of 56,885.
It is up +1.16% in the last 24 hours and down -63.42% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$1.32
Open:
$1.37
24h Volume:
56,885
Relative Volume:
0.10
Market Cap:
$1.16M
Revenue:
-
Net Income/Loss:
$-20.26M
P/E Ratio:
-0.1565
EPS:
-8.54
Net Cash Flow:
$-8.25M
1W Performance:
-0.35%
1M Performance:
-63.42%
6M Performance:
-84.34%
1Y Performance:
-95.72%
1-Day Range:
$1.3105
$1.3718
1-Week Range:
$1.30
$1.45
52-Week Range:
$1.30
$75.60
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
1.33 | 1.16M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.86 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.31 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.17 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.76 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.29 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Oragenics Inc Stock (OGEN) Latest News
Why Oragenics Inc. stock attracts strong analyst attention5x Profit Potential - Newser
Oragenics Announces Approval of Common Stock Listing on NYSE MKT - AOL.com
What analysts say about Oragenics Inc. stockRapid profit acceleration - Autocar Professional
What drives Oragenics Inc. stock priceExceptional profit velocity - Autocar Professional
Is Oragenics Inc. a good long term investmentExceptional ROI - Autocar Professional
Oragenics Partners With Sterling For U.S.-Based Manufacturing Of Concussion Drug ONP-002 - Nasdaq
Oragenics Inc. Secures U.S. Manufacturing Partner for Concussion Drug Ahead of Phase IIb Trials - citybuzz -
Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development - The Manila Times
Oragenics partners with Sterling for concussion drug production By Investing.com - Investing.com South Africa
Oragenics partners with Sterling for concussion drug production - Investing.com
What makes Oragenics Inc. stock price move sharplyHigh Probability Setups - Newser
How Oragenics Inc. stock performs during market volatilityFree Real-Time Market Predictions - Newser
Best Momentum Stock to Buy for July 7th - The Globe and Mail
Oragenics Soars 11.11% on $20M Capital Raise for Clinical Trials - AInvest
Oragenics Closes $16.5 Million Offering of Preferred Stock, Warrants - MarketScreener
Oragenics Raises $16.5M Through Public Offering - TipRanks
Oragenics, Inc. Successfully Closes $16.5 Million Public Offering of Series H Convertible Preferred Stock and Warrants - Nasdaq
Oragenics' Stock Takes A Hit With New Offering Announcement - Finimize
Form 424B5 ORAGENICS INC - StreetInsider
Oragenics shares plunge following announcement of $20 million preferred stock sale - MSN
Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D - citybuzz -
Oragenics stock tumbles after announcing $20 million preferred stock offering - Investing.com
Why Is Oragenics Stock (OGEN) Down 55% Today? - TipRanks
Oragenics announces $20 million preferred stock offering - Investing.com Australia
Oragenics, Inc. Announces $20 Million Public Offering of Series H Convertible Preferred Stock and Warrants - Nasdaq
Oragenics announces $20 million preferred stock offering By Investing.com - Investing.com UK
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants - TradingView
Major Shareholder Odyssey Health Sells Oragenics Stock! - TipRanks
Future of Oral Probiotic Supplements | Innovations in Oral - openPR.com
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Conferences - citybuzz -
Oragenics to Present at 2025 BIO International Convention and At - GuruFocus
Oragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium - Nasdaq
GlobeNewswire by Notified - The Manila Times
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium | OGEN Stock News - GuruFocus
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium - The Manila Times
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Oragenics to Present at 2025 BIO International Convention - GlobeNewswire
Top stock gains: US stocks posting the highest gains today - Yahoo
Rocket Lab Corporation (RKLB): A Bull Case Theory - Yahoo
Upstart Holdings, Inc. (UPST): A Bull Case Theory - Yahoo
Vireo Growth Inc. Announces Closing of Proper Brands Acquisition in Missouri - Yahoo
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea - Yahoo
Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews
Top Premarket Decliners - MarketScreener
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):